GH

Michael Brian Bell

Known title: Chief Financial OfficerCIK: 0001702824

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

Guardant Health Wins Patent Ruling, Morgan Stanley Lifts Target. Guardant Health secured a favorable decision from the U.S. Patent Trial and Appeal Board, which rejected a challenge to its core duplex sequencing patent. This legal win supports the company's position in the growing liquid biopsy market. Additionally, Morgan Stanley maintained an Overweight rating and raised its price target to $200, citing strong fundamentals in the diagnostics sector.

this person other insiders at GH

Transaction History

GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$684K
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$668K
GH▲ Buy$0
GH▼ Sell$142K
GH▼ Sell$257K
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$626K
GH▼ Sell$261K
GH▼ Sell$634K
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$1.3M
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$170K
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$896K
GH▼ Sell$262K
GH▼ Sell$331K
GH▲ Buy$965K
GH▲ Buy$763K
GH▼ Sell$815K
GH▼ Sell$2.3M
GH▼ Sell$781K
GH▼ Sell$1.2M
GH▼ Sell$594K
GH▼ Sell$523K
GH▼ Sell$350K
GH▼ Sell$128K
GH▼ Sell$26K
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$482K
GH▲ Buy$0
GH▼ Sell$91K
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$54K
GH▼ Sell$82K
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$45K
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$71K
GH▲ Buy$0
GH▼ Sell$108K
GH▼ Sell$111K
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$49K
GH▲ Buy$0
GH▼ Sell$26K
GH▼ Sell$58K
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$92K
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$44K
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$100K
GH▲ Buy$0
GH▼ Sell$8K
GH▲ Buy$0
GH▼ Sell$33K
GH▲ Buy$0
GH▼ Sell$12K
GH▲ Buy$0
GH▼ Sell$13K
GH▲ Buy$0
GH▼ Sell$16K
GH▲ Buy$0
GH▼ Sell$46K
GH▲ Buy$0
GH▼ Sell$40K
GH▼ Sell$97K
GH▲ Buy$0

We use analytics to understand how market-wall is used. No personal data is sold.